Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma

08:40 EDT 6 May 2014 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab Advancing New Phase 3 Studies with MK-3475 in Adjuv...

Other Sources for this Article

Merck
Media:
Ian McConnell, 973-901-5722
Claire Mulhearn, 908-423-7425
or
Investors:
Carol Ferguson, 908-423-4465
Justin Holko, 908-423-5088

NEXT ARTICLE

More From BioPortfolio on "Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.  Cancer sometimes begins in one part of the body before spre...

Gilotrif (afatinib)
Latest News Clinical Trials Research Drugs Reports Corporate
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Advertisement

Searches Linking to this Story